-
公开(公告)号:US20190192581A1
公开(公告)日:2019-06-27
申请号:US16051747
申请日:2018-08-01
发明人: Geoffrey von Maltzahn , Matthew R. Henn , David N. Cook , David Arthur Berry , Noubar B. Afeyan , Brian Goodman , Mary-Jane Lombardo McKenzie , Marin Vulic
IPC分类号: A61K35/741 , A61K45/06 , A61K35/742 , A61K9/48 , A61K35/747 , A61K35/745 , A61K35/744 , C12N1/20 , A61K35/74 , A61K9/00 , A61K35/37
CPC分类号: A61K35/741 , A61K9/0053 , A61K9/48 , A61K9/4816 , A61K35/37 , A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , C12N1/20 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481 , Y02A50/49
摘要: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore-form ing bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.
-
公开(公告)号:US20180177923A1
公开(公告)日:2018-06-28
申请号:US15902063
申请日:2018-02-22
发明人: Robert G. Matheny
IPC分类号: A61L27/54 , A61L27/36 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61L27/58 , A61L27/40 , A61L27/38 , A61L27/22 , A61K48/00 , A61K38/39 , A61K38/18 , A61K38/17 , A61K35/545 , A61K9/00
CPC分类号: A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
公开(公告)号:US20180125808A1
公开(公告)日:2018-05-10
申请号:US15860989
申请日:2018-01-03
CPC分类号: A61K31/295 , A01N37/10 , A01N37/36 , A01N37/44 , A01N43/40 , A01N55/02 , A01N59/16 , A23K20/10 , A23K20/30 , A23K50/10 , A23K50/30 , A23K50/75 , A61K35/12 , A61K35/36 , A61K35/37 , A61L2/16 , A61P31/04 , C09D5/14
摘要: A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.
-
公开(公告)号:US09867858B2
公开(公告)日:2018-01-16
申请号:US15017380
申请日:2016-02-05
发明人: Thomas Julius Borody
IPC分类号: A61K39/08 , A61K39/00 , A61K39/38 , A61K39/116 , A61K39/09 , A01N63/00 , A01N65/00 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号: A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号:US09855303B2
公开(公告)日:2018-01-02
申请号:US15415745
申请日:2017-01-25
发明人: Gregory McKenzie , Mary-Jane Lombardo McKenzie , David N. Cook , Marin Vulic , Geoffrey von Maltzahn , Brian Goodman , John Grant Aunins , Matthew R. Henn , David Arthur Berry , Jonathan Winkler
CPC分类号: A61K35/741 , A61K9/0053 , A61K9/48 , A61K9/4816 , A61K35/37 , A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61K45/06 , C12N1/20 , Y02A50/402 , Y02A50/469 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/48 , Y02A50/481
摘要: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
-
公开(公告)号:US20170367642A1
公开(公告)日:2017-12-28
申请号:US15521293
申请日:2016-06-14
申请人: HYGIEACARE, INC.
CPC分类号: A61B5/4255 , A61B5/42 , A61B5/6823 , A61B5/702 , A61B7/00 , A61B7/008 , A61B2505/05 , A61B2562/0204 , A61K35/37 , A61K2035/11 , A61M3/0204 , A61M3/0275 , A61M2205/3375 , A61M2210/1064 , C12Q1/04
摘要: Systems, kits and methods are provided, which analyze the large intestine content and utilize acoustic signals detected during delivery of water into the large intestine and drained large intestine contents to derive large intestine characteristics such as microbiotal analysis. Systems may include a water delivery unit including a water supply and a nozzle connected thereto, configured to introduce water controllably into a patient's large intestine, and an analysis unit that provides information about the drained contents using optical examination or biological assays. The information may be related to acoustic analysis of signals from acoustic sensors that are attachable to a patient's abdomen. A variety of sensor configurations, positioning options, analysis strategies and large intestine characteristics are presented.
-
公开(公告)号:US20160279176A1
公开(公告)日:2016-09-29
申请号:US15173134
申请日:2016-06-03
IPC分类号: A61K35/74 , A61K9/00 , A61K35/24 , A61K35/742
CPC分类号: A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/473 , Y02A50/475 , A61K2300/00
摘要: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
摘要翻译: 本发明提供了包含人类粪便提取物的组合物和使用这些组合物的方法,包括用于替代或补充或修饰受试者的结肠微生物群的方法,以及用于治疗患者的疾病,病理状况和/或医源性病症的方法 结肠。
-
公开(公告)号:US09295758B2
公开(公告)日:2016-03-29
申请号:US14193008
申请日:2014-02-28
发明人: Robert G Matheny
IPC分类号: A61L27/36 , A61L27/54 , A61K35/38 , A61K35/34 , A61K48/00 , A61L27/38 , A61L27/40 , A61K38/17 , A61K38/18 , A61K35/545 , A61K31/726 , A61K31/7088 , A61K35/37 , A61K35/407 , A61K35/22 , A61K38/39 , A61L27/58 , A61K35/50 , A61K9/00
CPC分类号: A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
公开(公告)号:US09283302B2
公开(公告)日:2016-03-15
申请号:US13896424
申请日:2013-05-17
发明人: Robert G Matheny
IPC分类号: A61K35/12 , A61K9/16 , A61F13/00 , A61L33/00 , A61N1/362 , A61L27/36 , A61L31/00 , A61F2/02 , A61L27/54 , A61K35/38 , A61K35/22 , A61F2/24 , A61K38/00
CPC分类号: A61L27/3629 , A61F2/0077 , A61F2/02 , A61F2/24 , A61F2002/0086 , A61F2210/0076 , A61K35/12 , A61K35/22 , A61K35/37 , A61K35/38 , A61K35/42 , A61K38/005 , A61K38/1825 , A61L27/227 , A61L27/34 , A61L27/3604 , A61L27/362 , A61L27/3625 , A61L27/3633 , A61L27/3679 , A61L27/3683 , A61L27/38 , A61L27/3804 , A61L27/3834 , A61L27/50 , A61L27/54 , A61L31/005 , A61L31/041 , A61L31/14 , A61L31/16 , A61L2300/20 , A61L2300/23 , A61L2300/25 , A61L2300/252 , A61L2300/40 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/414 , A61L2300/418 , A61L2300/434 , A61L2300/45 , A61L2300/64 , A61L2400/02 , A61L2400/12 , A61L2400/18 , A61L2430/20 , A61N1/375 , A61N1/3752
摘要: A remodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region and at least one lead conduit, the internal region being configured to receive a device therein, the lead conduit being configures to receive at least one device lead therein, the bioremodelable material comprising an extracellular matrix (ECM) composition that includes an ECM component derived from a mammalian source.
摘要翻译: 一种可重塑的包装结构,包括由至少一片生物可重塑材料形成的袋,所述袋包括内部区域和至少一个引线导管,所述内部区域被配置为在其中容纳装置,所述引线导管配置为至少接收 所述生物可重塑材料包含细胞外基质(ECM)组合物,其包含源自哺乳动物来源的ECM组分。
-
公开(公告)号:US20160038644A1
公开(公告)日:2016-02-11
申请号:US14269874
申请日:2014-05-05
申请人: Robert G. Matheny
发明人: Robert G. Matheny
CPC分类号: A61L27/54 , A61K9/0019 , A61K31/7088 , A61K31/726 , A61K35/22 , A61K35/34 , A61K35/37 , A61K35/38 , A61K35/407 , A61K35/50 , A61K35/545 , A61K38/1741 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K48/00 , A61L27/227 , A61L27/3629 , A61L27/3633 , A61L27/367 , A61L27/3683 , A61L27/3687 , A61L27/3834 , A61L27/3873 , A61L27/40 , A61L27/58 , A61L2300/412 , A61L2300/414 , A61L2300/426 , A61L2300/45 , A61L2300/64 , A61L2400/06 , A61L2430/20 , A61L2430/30
摘要: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
-
-
-
-
-
-
-
-
-